Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Granules India's US...

    Granules India's US arm launches generic Methergine tablets in US market

    Written by Ruby Khatun Khatun Published On 2018-06-02T10:15:15+05:30  |  Updated On 2 Jun 2018 10:15 AM IST
    Granules Indias US arm launches generic Methergine tablets in US market

    New Delhi: Granules India Ltd said its US subsidiary has launched the generic version of Methergine (Methylergonovine Maleate) tablets, in partnership with West-Ward Pharmaceuticals Corp, a wholly-owned subsidiary of Hikma Pharmaceuticals PLC.


    Methylergonovine is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum haemorrhage. A press release issued by Granules said this is the first product that the company has commercialized from its R&D and manufacturing facility in Virginia.


    "We are happy to have collaborated with Hikma. Apart from the fact that Hikma has a proven history of being a responsible player in the market, we look at this launch as the inception towards building a strategic relationship."


    "The launch of generic Methergine tablets plays into our strategy of identifying patient needs and catering to them with economical alternatives," Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc, said.




    Brian Hoffmann, President of West-Ward, said, "We are very pleased to be entering into a partnership with Granules Pharmaceuticals, Inc., adding this important oxytocic agent to our product portfolio in the US." "This partnership demonstrates our focus on improving patients access to high-quality, affordable medicines," he said.

    Brian HoffmanngenericGranules IndiaHikma Pharmaceuticals PlclaunchesMethergine tabletsmethylergonovine maleatepartnershipPriyanka ChigurupatiUS armUS marketWard Pharmaceuticals Corp
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok